Molecular Dynamics Investigation on a Series of HIV Protease Inhibitors: Assessing the Performance of MM-PBSA and MM-GBSA Approaches

The binding free energies (ΔG(Bind)) obtained from molecular mechanics with Poisson-Boltzmann surface area (MM-PBSA) or molecular mechanics with Generalized Born surface area (MM-GBSA) calculations using molecular dynamics (MD) trajectories are the most popular procedures to measure the strength of interactions between a ligand and its receptor. Several attempts have been made to correlate the ΔG(Bind) and experimental IC(50) values in order to observe the relationship between binding strength of a ligand (with its receptor) and its inhibitory activity. The duration of MD simulations seems very important for getting acceptable correlation. Here, we are presenting a systematic study to estimate the reasonable MD simulation time for acceptable correlation between ΔG(Bind) and experimental IC(50) values. A comparison between MM-PBSA and MM-GBSA approaches is also presented at various time scales. MD simulations (10 ns) for 14 HIV protease inhibitors have been carried out by using the Amber program. MM-PBSA/GBSA based ΔG(Bind) have been calculated and correlated with experimental IC(50) values at different time scales (0-1 to 0-10 ns). This study clearly demonstrates that the MM-PBSA based ΔG(Bind) (ΔG(Bind)-PB) values provide very good correlation with experimental IC(50) values (quantitative and qualitative) when MD simulation is carried out for a longer time; however, MM-GBSA based ΔG(Bind) (ΔG(Bind)-GB) values show acceptable correlation for shorter time of simulation also. The accuracy of ΔG(Bind)-PB increases and ΔG(Bind)-GB remains almost constant with the increasing time of simulation.

[1]  P A Kollman,et al.  Continuum solvent studies of the stability of RNA hairpin loops and helices. , 1998, Journal of biomolecular structure & dynamics.

[2]  G Narahari Sastry,et al.  The efficacy of conceptual DFT descriptors and docking scores on the QSAR models of HIV protease inhibitors. , 2012, Medicinal chemistry (Shariqah (United Arab Emirates)).

[3]  Hemant Kumar Srivastava,et al.  Quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine (PBD) conjugates: Design, synthesis and biological evaluation as potential anticancer agents. , 2010, Bioorganic & medicinal chemistry.

[4]  Stefano Alcaro,et al.  Molecular Dynamics and Free Energy Studies on the Wild-Type and Mutated HIV-1 Protease Complexed with Four Approved Drugs: Mechanism of Binding and Drug Resistance , 2009, J. Chem. Inf. Model..

[5]  Asim Kumar Debnath,et al.  Comparative Molecular Field Analysis (CoMFA) of a Series of Symmetrical Bis-Benzamide Cyclic Urea Derivatives as HIV-1 Protease Inhibitors , 1998, J. Chem. Inf. Comput. Sci..

[6]  A Srinivas Reddy,et al.  Virtual screening in drug discovery -- a computational perspective. , 2007, Current protein & peptide science.

[7]  Biswa Ranjan Meher,et al.  Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies. , 2012, The journal of physical chemistry. B.

[8]  D. J. Price,et al.  Assessing scoring functions for protein-ligand interactions. , 2004, Journal of medicinal chemistry.

[9]  Thomas Simonson,et al.  Free energy simulations come of age: protein-ligand recognition. , 2002, Accounts of chemical research.

[10]  Ajay,et al.  Computational methods to predict binding free energy in ligand-receptor complexes. , 1995, Journal of medicinal chemistry.

[11]  M L Lamb,et al.  Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. , 1998, Journal of medicinal chemistry.

[12]  G Narahari Sastry,et al.  Virtual high throughput screening in new lead identification. , 2011, Combinatorial chemistry & high throughput screening.

[13]  J. Kirkwood.  Statistical Mechanics of Fluid Mixtures , 1935 .

[14]  Araz Jakalian,et al.  Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: I. Method , 2000 .

[15]  P. Sexton,et al.  Drug transporters in drug efficacy and toxicity. , 2012, Annual review of pharmacology and toxicology.

[16]  Stefano Alcaro,et al.  A “quasi‐flexible” automatic docking processing for studying stereoselective recognition mechanisms. Part I. Protocol validation , 2000, J. Comput. Chem..

[17]  Richard A. Bryce,et al.  Assessment of QM/MM Scoring Functions for Molecular Docking to HIV-1 Protease , 2009, J. Chem. Inf. Model..

[18]  E A Emini,et al.  Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors. , 2000, Journal of medicinal chemistry.

[19]  J Tirado-Rives,et al.  Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations. , 2001, Journal of medicinal chemistry.

[20]  K D Watenpaugh,et al.  Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. , 1998, Journal of medicinal chemistry.

[21]  Parimal Kar,et al.  Origin of decrease in potency of darunavir and two related antiviral inhibitors against HIV-2 compared to HIV-1 protease. , 2012, The journal of physical chemistry. B.

[22]  Peter A. Kollman,et al.  FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .

[23]  Jens Carlsson,et al.  Combining docking, molecular dynamics and the linear interaction energy method to predict binding modes and affinities for non-nucleoside inhibitors to HIV-1 reverse transcriptase. , 2008, Journal of medicinal chemistry.

[24]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[25]  Olivier Michielin,et al.  Protein-ligand binding free energy estimation using molecular mechanics and continuum electrostatics. Application to HIV-1 protease inhibitors , 2003, J. Comput. Aided Mol. Des..

[26]  Amedeo Caflisch,et al.  How Does Darunavir Prevent HIV-1 Protease Dimerization? , 2012, Journal of chemical theory and computation.

[27]  B. Kuhn,et al.  Validation and use of the MM-PBSA approach for drug discovery. , 2005, Journal of medicinal chemistry.

[28]  G Narahari Sastry,et al.  Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors. , 2007, Journal of molecular graphics & modelling.

[29]  G. Narahari Sastry,et al.  Comparison of Computational Methods to Model DNA Minor Groove Binders , 2011, J. Chem. Inf. Model..

[30]  C H Chang,et al.  Design, synthesis, and evaluation of tetrahydropyrimidinones as an example of a general approach to nonpeptide HIV protease inhibitors. , 1997, Journal of medicinal chemistry.

[31]  Marco Pierini,et al.  “Quasi flexible” automatic docking processing for studying stereoselective recognition mechanisms, part 2: Prediction of ΔΔG of complexation and 1H‐NMR NOE correlation , 2007, J. Comput. Chem..

[32]  M. Gilson,et al.  The statistical-thermodynamic basis for computation of binding affinities: a critical review. , 1997, Biophysical journal.

[33]  Ping Chen,et al.  Aminodiol HIV protease inhibitors. Synthesis and structure-activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicity. , 1996, Journal of medicinal chemistry.

[34]  Baohua Ji,et al.  Strength of Hydrogen Bond Network Takes Crucial Roles in the Dissociation Process of Inhibitors from the HIV-1 Protease Binding Pocket , 2011, PloS one.

[35]  Tingjun Hou,et al.  Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance. , 2007, Journal of medicinal chemistry.

[36]  Markus A. Lill,et al.  Solvent Interaction Energy Calculations on Molecular Dynamics Trajectories: Increasing the Efficiency Using Systematic Frame Selection , 2011, J. Chem. Inf. Model..

[37]  Georgios Leonis,et al.  Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations. , 2012, Journal of medicinal chemistry.

[38]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[39]  P. Lam,et al.  Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency. , 1998, Journal of medicinal chemistry.

[40]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[41]  J. Barrish,et al.  Aminodiol HIV protease inhibitors. 1. Design, synthesis, and preliminary SAR. , 1994, Journal of medicinal chemistry.

[42]  Mayuso Kuno,et al.  Binding energy analysis for wild‐type and Y181C mutant HIV‐1 RT/8‐Cl TIBO complex structures: Quantum chemical calculations based on the ONIOM method , 2005, Proteins.

[43]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[44]  Sergio Martí,et al.  A quantum mechanics/molecular mechanics study of the protein-ligand interaction for inhibitors of HIV-1 integrase. , 2007, Chemistry.

[45]  Peter V. Coveney,et al.  Accurate Ensemble Molecular Dynamics Binding Free Energy Ranking of Multidrug-Resistant HIV-1 Proteases , 2010, J. Chem. Inf. Model..

[46]  L. Tong,et al.  2',6'-Dimethylphenoxyacetyl: a new achiral high affinity P(3)-P(2) ligand for peptidomimetic-based HIV protease inhibitors. , 2000, Journal of medicinal chemistry.

[47]  Peter V Coveney,et al.  Rapid and accurate prediction of binding free energies for saquinavir-bound HIV-1 proteases. , 2008, Journal of the American Chemical Society.

[48]  B. Jayaram,et al.  Free energy component analysis for drug design: a case study of HIV-1 protease-inhibitor binding. , 2001, Journal of medicinal chemistry.

[49]  Ray Luo,et al.  Accelerated Poisson–Boltzmann calculations for static and dynamic systems , 2002, J. Comput. Chem..

[50]  Irene T. Weber,et al.  Amprenavir complexes with HIV‐1 protease and its drug‐resistant mutants altering hydrophobic clusters , 2010, The FEBS journal.

[51]  Alexandre Varnek,et al.  Anti-HIV Activity of HEPT, TIBO, and Cyclic Urea Derivatives: Structure-Property Studies, Focused Combinatorial Library Generation, and Hits Selection Using Substructural Molecular Fragments Method , 2003, J. Chem. Inf. Comput. Sci..

[52]  Ahmed Kamal,et al.  Synthesis of bis-1,2,3-triazolo-bridged unsymmetrical pyrrolobenzodiazepine trimers via ‘click’ chemistry and their DNA-binding studies , 2010 .

[53]  W. L. Jorgensen.  Free energy calculations: a breakthrough for modeling organic chemistry in solution , 1989 .

[54]  D. Walters,et al.  Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation. , 1996, Journal of medicinal chemistry.

[55]  P. Kollman,et al.  Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. , 2001, Journal of the American Chemical Society.

[56]  Wei Zhang,et al.  Predicting drug resistance of the HIV‐1 protease using molecular interaction energy components , 2009, Proteins.

[57]  E A Emini,et al.  3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors. , 1993, Journal of medicinal chemistry.

[58]  R. Zwanzig.  High‐Temperature Equation of State by a Perturbation Method. I. Nonpolar Gases , 1954 .

[59]  Mohammed H Bohari,et al.  Modeling anti-HIV compounds: the role of analogue-based approaches. , 2012, Current computer-aided drug design.

[60]  S. Hagen,et al.  Nonpeptide inhibitors of HIV protease , 2000 .

[61]  A Wlodawer,et al.  Structural and biochemical studies of retroviral proteases. , 2000, Biochimica et biophysica acta.

[62]  S E Hagen,et al.  4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters. , 2001, Journal of medicinal chemistry.

[63]  W W Wilkerson,et al.  Nonsymmetrically substituted cyclic urea HIV protease inhibitors. , 1997, Journal of medicinal chemistry.

[64]  C. E. Peishoff,et al.  A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.

[65]  J. Aqvist,et al.  A new method for predicting binding affinity in computer-aided drug design. , 1994, Protein engineering.

[66]  G Narahari Sastry,et al.  Efficient estimation of MMGBSA-based BEs for DNA and aromatic furan amidino derivatives , 2013, Journal of biomolecular structure & dynamics.